We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Benchmark Holdings plc (BMK) Ordinary Shares

Sell:36.80p Buy:37.90p 0 Change: 2.65p (6.62%)
Market closed Prices as at close on 16 August 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Bid situation
Sell:36.80p
Buy:37.90p
Change: 2.65p (6.62%)
Market closed Prices as at close on 16 August 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Bid situation
Sell:36.80p
Buy:37.90p
Change: 2.65p (6.62%)
Market closed Prices as at close on 16 August 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Bid situation
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Benchmark Holdings plc is a United Kingdom-based aquaculture biotechnology company. The Company is focused on providing specialized mission-critical solutions in three complementary areas: genetics, health, and advanced nutrition. The Company operates through three segments: Genetics, Advanced Nutrition, and Health. The Genetics segment is salmon breeding technology combined with production facilities to provide a range of genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the global aquaculture industry. The Health segment is focused on providing health products to the global aquaculture market. The Company has portfolio of various aquaculture species, such as salmon, shrimp, sea bass and sea bream, and tilapia in all the aquaculture regions around the world.

Contact details

Address:
4 Park Square
Thorncliffe Park, Chapeltown
SHEFFIELD
S35 2PH
United Kingdom
Telephone:
+44 (0114) 2409939
Website:
https://www.benchmarkplc.com/

Important dates

Future events
There are no future events available.
Past events
Quarter 3 results 05 August 2024 05/08/24
Interim results 22 May 2024 22/05/24
Quarterly results 22 May 2024 22/05/24
Quarter 2 results 22 May 2024 22/05/24
Quarterly results 15 February 2024 15/02/24
AGM 08 February 2024 08/02/24
Final results 29 November 2023 29/11/23
Quarter 4 results 29 November 2023 29/11/23
Quarter 3 results 24 August 2023 24/08/23

General stock information

EPIC:
BMK
ISIN:
GB00BGHPT808
Market cap:
£273.72 million
Shares in issue:
739.78 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Trond Williksen
    Chief Executive Officer, Executive Director
  • Septima Maguire
    Chief Financial Officer, Executive Director
  • Corina Holmes
    Group Head of People
  • Ivonne Cantu
    Director - Investor Relations and Corporate Development
  • Ross Houston
    Director - Genetics & Innovation
  • Geir Melingen
    Head - Salmon, Health & Genetics
  • Patrick Waty
    Head of Advanced Nutrition
  • Jennifer Haddouk
    Company Secretary, Group Legal Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.